| Literature DB >> 23300139 |
Sarah K McGill1, Evangelos Evangelou, John P A Ioannidis, Roy M Soetikno, Tonya Kaltenbach.
Abstract
PURPOSE: Many studies have reported on the use of narrow band imaging (NBI) colonoscopy to differentiate neoplastic from non-neoplastic colorectal polyps. It has potential to replace pathological diagnosis of diminutive polyps. We aimed to perform a systematic review and meta-analysis on the real-time diagnostic operating characteristics of NBI colonoscopy.Entities:
Keywords: Colonic Polyps; Colonoscopy; Colorectal Cancer Screening; Colorectal Neoplasia; Meta-Analysis
Mesh:
Year: 2013 PMID: 23300139 PMCID: PMC3841766 DOI: 10.1136/gutjnl-2012-303965
Source DB: PubMed Journal: Gut ISSN: 0017-5749 Impact factor: 23.059
Figure 1Endoscopic image with narrow band imaging of diminutive colorectal polyps. (A) Adenoma and (B) non-neoplastic polyp.
Figure 2Flow chart of the search strategy and selected studies.
Study characteristics
| Study, year | Study no. | Country | Diagnostic modality | Diagnostic criteria | Endoscopists number | No. of experts | Patients analysed | Polyps analysed | No. of neoplasms/No. of non-neoplasms | Polyps, n (%) with high confidence predictions |
|---|---|---|---|---|---|---|---|---|---|---|
| Buchner | 1 | USA | Exera | Kudo | 2 | 2 | 75 | 41 | 25/16 | |
| Henry | 2 | USA | Exera | Sano-Emura | 1 | 1 | 52 | 126 | 67/59 | |
| Hirata | 3 | Japan | Lucera | Brown hue | 2 | 2 | 99 | 148 | 132/16 | |
| Ignjatovic | 4 | UK | Lucera | Vascular pattern intensity | 4 | 2 | 130 | 169 | 129/40 | * |
| Lee | 5 | South Korea | Lucera | Mucosal pattern and vascular density | 1 | 1 | 142 | 156 | 80/76 | 125 (80.1%) |
| Machida | 6 | Japan | Lucera | Kudo | 2 | 2 | 34 | 43 | 34/9 | |
| Rastogi | 7 | USA | Exera | Type A: HP | 1 | 1 | 101 | 236 | 143/93 | |
| Type B: TA | ||||||||||
| Rastogi | 8 | USA | Exera | Type A: HP | 6 | 6 | 134 | 384 | 147/237 | |
| Type B: TA | ||||||||||
| Rex (2009) | 9 | USA | Exera | Pre NICE* | 1 | 1 | 136 | 451 | 230/221 | 368 (81.6%) |
| Rogart | 10 | USA | Exera | Vascular density, modified Kudo | 4 | 4 | 302 | 265 | 129/134 | |
| Rotondano | 11 | Italy | Lucera | Kudo | 3 | 3 | 94 | 281 | 141/140 | |
| Sakamoto | 12 | Japan | Lucera | Sano | 1 | 1 | 80 | 116 | 52/42 | |
| Sano | 13 | Japan | Lucera | Sano | 1 | 1 | 92 | 150 | 111/39 | |
| Shahid | 14 | USA | Exera | Sano | 1 | 1 | 65 | 130 | 58/72 | |
| Singh | 15 | Australia | Exera | Sano | 1 | 1 | 32 | 50 | 30/20 | 50 (100%) |
| Zhou | 16 | China | Lucera | Kudo and Sano | 1 | 1 | 118 | 109 | 67/42 | |
| Ren (2012) | 17 | China | Exera | Yoshiki | 1 | 1 | 75 | 116 | 52/42 | |
| Kuiper | 18 | The Netherlands | Exera | Kudo | 3 | 0 | 108 | 281 | 141/140 | 231 (82.2%) |
| Abstracts | ||||||||||
| Coe | 19 | USA | Exera | NICE | 6 | 6 | 300 | 260 | 152/108 | |
| Hewett and Rex (2010) | 20 | USA | Exera | Pre NICE* | 1 | 1 | 225 | 235 | 38/197 | |
| Kaltenbach | 21 | USA | Exera | NICE | 2 | 2 | 220 | 236 | 146/90 | 178 (75.4%) |
| Kaltenbach | 22 | USA | Exera | NICE | 5 | 5 | 311 | 338 | 233/105 | 246 (72.8%) |
| Matthew | 23 | USA | Exera | Reported patterns | 1 | 0 | 100 | 231 | 106/125 | |
| Occhipinti | 24 | Italy | Exera | Kudo | 5 | 5 | 93 | 220 | 120/100 | |
| Pohl | 25 | USA | Exera | NICE | 10 | NR | 608 | 948 | 528/420 | 770 (81.3%) |
| Radaelli | 26 | Italy | Exera | NR | NR | all | 197 | 354 | 233/121 | 354* |
| Ringold | 27 | USA | Exera | ‘Cerebriform’ | 4 | 4 | 55 | 93 | 56/37 | |
| Yague | 28 | Spain | Exera | Vascular patterns | 1 | 1 | 75 | 215 | 107/108 | |
*Information on the number of polyps predicted with low confidence was not provided.
NICE, Narrow Band Imaging International Colorectal Endoscopic Classification. This classification system includes criteria on polyp colour, vessels and surface pattern; NR, not reported; Pre NICE, classification systems based on similar criteria that preceded NICE.
The quality assessment of diagnostic accuracy studies-2 tool for quality assessment of the included studies
| Author | DOM1A1 | DOM1A2 | DOM1A3 | DOM 1A4 | DOM1B | DOM2A1 | DOM 2A2 | DOM 2A3 | DOM 2B | DOM 3A1 | DOM 3A2 | DOM 3A3 | DOM 3B | DOM 4A1 | DOM 4A2 | DOM4A3 | DOM4A4 | DOM 4A5 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Buchner | Y | Y | Y | L | L | Y | Y | L | L | Y | Y | L | L | U | Y | Y | Y | L |
| Henry | Y | Y | Y | L | L | Y | Y | L | L | Y | U | U | U | Y | Y | Y | Y | L |
| Hirata | U | Y | U | U | H | Y | Y | L | U | Y | Y | L | L | Y | Y | Y | U | U |
| Ignjatovic | Y | Y | Y | L | H | Y | Y | L | L | Y | Y | L | L | U | Y | Y | N | L |
| Lee | Y | Y | Y | L | L | Y | Y | L | U | Y | Y | L | L | Y | Y | Y | Y | L |
| Machida | U | Y | U | U | U | Y | Y | L | L | Y | U | U | L | Y | Y | U | U | U |
| Rastogi | U | Y | Y | U | L | Y | Y | L | L | Y | Y | L | L | Y | Y | Y | Y | L |
| Rastogi | U | Y | Y | U | L | Y | Y | L | L | Y | Y | L | L | Y | Y | Y | N | U |
| Rex | U | Y | U | U | U | Y | Y | L | L | Y | Y | L | L | U | Y | Y | U | U |
| Rogart | Y | Y | Y | L | L | Y | Y | L | L | Y | Y | L | L | U | Y | Y | U | U |
| Rotondano | U | Y | Y | L | L | Y | Y | L | H | Y | Y | L | L | Y | Y | Y | Y | L |
| Sakamoto | Y | Y | U | U | L | Y | Y | H | H | Y | Y | L | L | U | Y | Y | Y | L |
| Sano | Y | Y | Y | L | L | Y | Y | L | L | Y | Y | L | L | U | Y | Y | Y | L |
| Shahid | Y | Y | U | U | L | Y | Y | L | L | Y | Y | L | L | U | Y | Y | U | U |
| Singh | U | Y | Y | U | L | Y | Y | L | L | Y | Y | L | L | U | Y | Y | Y | L |
| Zhou | U | Y | Y | L | L | Y | Y | L | L | Y | Y | L | L | Y | Y | Y | Y | L |
| Ren | U | Y | Y | U | L | Y | Y | L | L | Y | U | U | L | Y | Y | Y | N | U |
| Kuiper | U | Y | Y | U | L | Y | Y | L | L | Y | Y | L | L | Y | Y | Y | Y | L |
| Abstracts | ||||||||||||||||||
| Coe | U | Y | U | U | L | Y | Y | L | L | Y | Y | L | L | Y | Y | U | Y | L |
| Hewett | U | Y | U | U | U | Y | U | U | L | Y | Y | L | L | Y | Y | Y | N | U |
| Kaltenbach | Y | Y | Y | L | L | Y | Y | L | L | Y | Y | L | L | Y | Y | Y | Y | L |
| Kaltenbach | Y | Y | Y | L | L | Y | Y | L | L | Y | Y | L | L | Y | Y | Y | Y | L |
| Matthew | Y | Y | Y | L | L | Y | U | U | L | Y | U | U | L | U | Y | Y | Y | L |
| Occhipinti | Y | Y | U | U | L | Y | Y | L | L | Y | U | L | L | Y | Y | Y | U | U |
| Pohl | U | Y | U | U | L | Y | Y | L | L | Y | U | U | L | Y | Y | Y | U | U |
| Radaelli | Y | Y | Y | L | L | Y | U | U | L | Y | Y | L | L | Y | Y | Y | Y | L |
| Ringold | U | Y | Y | U | L | Y | Y | L | L | Y | U | U | L | U | Y | Y | U | U |
| Yague | U | Y | U | U | L | Y | Y | L | L | Y | U | U | U | Y | Y | Y | U | U |
DOM, domain; DOM1A1, consecutive or random sample of patients enrolled; DOM1A2, case–control design avoided; DOM1A3, study avoided inappropriate exclusions; DOM1A4, selection of patients introduced bias; DOM1B, concern that included patients do not match the review question; DOM2A1, index test results interpreted without knowledge of results of reference standard; DOM2A2, prespecified threshold used; DOM2A3, could the conduct of index test have introduced bias; Dom2B, concern that index test conduct or interpretation differ from review question; DOM3A1, reference standard correctly classifies condition; DOM3A2, reference standard results interpreted independently from index test results; DOM3A3, could the reference standard, its conduct, or its interpretation have introduced bias; DOM3B, concern that target condition defined by reference standard does not match review question; DOM4A1, appropriate interval between index test and reference standard; DOM4A2, all patients received the reference standard; DOM4A3, patients received the same reference standard; DOM4A4, all patients included in the analysis; DOM4A5, could the patient flow have introduced bias; H, high; L, low; N, no; U, unclear; Y, yes.
Figure 3Hierarchical summary receiver-operating characteristic (HSROC) curve for the diagnostic performance of narrow band imaging to diagnose neoplastic and non-neoplastic polyps among all studies (blue line) and among published studies (green line). The size of the circles indicates the weight of the individual studies. The summary sensitivity and specificity is shown with a yellow square and the 95% confidence region is plotted. For all studies, the area under the HSROC curve was 0.92 (95% CI 0.90 to 0.94); for published studies, the area under the HSROC curve was 0.93 (0.90 to 0.95).
Figure 4Hierarchical summary receiver-operating characteristic (HSROC) curve for the diagnostic performance of narrow band imaging to diagnose diminutive polyps (blue line) and diminutive polyps that were diagnosed with high confidence (green line). For high-confidence predictions of diminutive polyps, area under the HSROC curve was 0.94 (95% CI 0.92 to 0.96).
Diagnostic accuracy of endoscopic diagnosis with NBI to distinguish between neoplastic and non-neoplastic colorectal neoplasms
| Summary estimates (95% CI) | Likelihood ratio (95% CI) | |||||
|---|---|---|---|---|---|---|
| Study characteristics | No. of studies (no. of polyps) | Sens | Spec | LR+ | LR− | Area under HSROC curve (95% CI) |
| All | 28 (6280) | 91.0 (87.6 to 93.5) | 82.6 (79.0 to 85.7) | 5.2 (4.3 to 6.4) | 0.11 (0.08 to 0.15) | 0.92 (0.90 to 0.94) |
| Published manuscripts | 18 (3212) | 91.7 (87.1 to 97.4) | 84.5 (80.4 to 87.9) | 5.9 (4.6 to 7.6) | 0.10 (0.06–0.16) | 0.93 (0.90–0.95) |
| High-confidence predictions | 8 (2146) | 93.8 (90.1 to 96.2) | 83.3 (77.1 to 88.1) | 5.6 (4.0 to 7.8) | 0.07 (0.05 to 0.12) | 0.95 (0.93 to 0.97) |
| Polyps ≤5 mm | 7 (1942) | 86.3 (78.4 to 91.7) | 84.1 (75.5 to 90.1) | 5.4 (3.6 to 8.2) | 0.16 (0.11 to 0.25) | 0.92 (0.89 to 0.94) |
| High-confidence predictions for polyps ≤5 mm | 5 (1350) | 93.4 (87.4 to 96.7) | 84.0 (76.6 to 89.3) | 5.8 (4.0 to 8.6) | 0.08 (0.04 to 0.15) | 0.94 (0.92 to 0.96) |
| Exera | 20 (5148) | 89.4 (85.0 to 92.6) | 81.6 (77.3 to 85.2) | 4.9 (3.9 to 6.0) | 0.13 (0.09 to 0.18) | 0.91 (0.89 to 0.94) |
| Lucera | 8 (1132) | 94.0 (88.7 to 96.9) | 86.0 (81.1 to 89.8) | 6.7 (4.9 to 9.2) | 0.07 (0.04 to 0.13) | 0.95 (0.93 to 0.97) |
| Highest-quality studies | 5 (826) | 91.5 (86.0 to 94.8) | 87.2 (74.7 to 94.1) | 7.2 (3.4 to 15.0) | 0.10 (0.06 to 0.16) | 0.95 (0.93 to 0.97) |
| High-quality studies | 12 (2428) | 88.3 (83.6 to 91.8) | 85.3 (80.3 to 89.2) | 6.0 (4.3 to 8.4) | 0.14 (0.09 to 0.20) | 0.93 (0.91 to 0.95) |
HSROC, hierarchical summary receiver-operating characteristic; NBI, narrow band imaging.
Figure 5Disagreement between endoscopically directed and pathology directed surveillance intervals. Each dot represents patients whose endoscopic-directed surveillance interval differed from that dictated by the pathological assessment. Discordant intervals in 22 patients in the study by Pohl et al40 are not plotted, as this information was not reported.
Figure 6Sensitivities and specificities of individual studies (see study numbers, table 1) plotted with the hierarchical summary receiver-operating characteristic (SROC) curve.